Stay updated with breaking news from Initial Results. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Nineteen abstracts accepted, including multiple presentations on the safety and efficacy of investigational epcoritamab (DuoBody-CD3xCD20) in a variety of treatment settings and hematologic malignancies
- Achieved $23.6 million in Total Revenue in the Third Quarter of 2022 Including $8.3 million in Net Revenue from Sales of COSELA® (trilaciclib) - -...
Newly published poster on the single-arm 27-patient safety and dosimetry lead-in provides key updates including: A median rPFS time of 11.5 months A...
Short-sellers appear to be pouncing on an upcoming scientific presentation.
INDIANAPOLIS, Sept. 04, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. PNT (the "Company" or "POINT"), a company accelerating the discovery, dev